Company intelligence / Profile preview

Xequel Bio

Fort Worth, Texas, USAxequel.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Xequel Bio has developed a proprietary peptide technology platform based on the alpha‑Connexin carboxyl‑Terminal peptide family. Its lead product, Granexin® Gel, has advanced through multiple clinical trials targeting wound healing and inflammatory skin conditions. The company’s pipeline includes topical formulations for chronic wounds as well as ophthalmic solutions. Clinical results have shown promise in modulating excessive inflammation and improving tissue regeneration outcomes.[2][3]

Therapeutic areas: PulmonologyOphthalmologyImmunologyDermatologyNeurology
Modalities: Synthetic peptides (notably aCT1 peptide)Recombinant polypeptides[4]Interleukins[4]
Industry: Biotech

Drug pipeline

4 assets

zifogaptide

3 more assets in the full pipeline.

Request access →

Partnerships

Exclusive license from Medical University of South Carolina; no major pharma partnerships disclosed.[2]

Beyond the preview

Go deeper on Xequel Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xequel Bio.

Explore the full profile